Vaccines for covid-19 patients
As part of the COVID-NMA initiative, we are identifying all randomized controlled trials (RCTs) of COVID-19 vaccine.
Below, you can access
- A table with the general characteristics and risk of bias assessment for all RCTs identified.
- A synthesis with forest plots and summary of findings table/evidence profile including phase 2-3 trials. For the vaccine (dose and schedule) evaluated in phase 2-3 trials, results available for the same vaccine (dose and schedule) in phase 1-2 trial will also be included in the synthesis.
Of note: For risk of bias assessment, we are considering the “effect of assignment to intervention” which might not be the analysis planned and reported by investigators. Consequently, when investigators planned to assess and report the “per-protocol” effect, the risk of bias for domain 2 may be evaluated as “some concerns”. We will contact investigators to obtain the results of the intent-to-treat analysis.
We present the risk of Bias for phase 1-2 studies assessed for safety outcomes only.
Treatment comparisons
We report below the forest plots for the main treatment comparisons.
Please choose a Treatment Comparison:
- Ad26.COV2.S (5×10^10 vp) D0 vs Placebo (Janssen Biotech, Inc.)
- ChAdOx1 vs MenACWY (University of Oxford/AstraZeneca )
- Gam-COVID-Vac rAd26-S/rAd5-S vs Placebo (Gamaleya Research Institute of Epidemiology and Microbiology)
- BNT162b2 vs Placebo (BioNTech/Fosun Pharma/Pfizer )
- mRNA-1273 vs Placebo (ModernaTX)
Press releases
We acknowledged the publication of press release on the findings of the Novavax vaccine: COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial ">Novavax vaccine We will summarize and assess the study results once the full study reports have been published.Last update: 16/04/2021
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04470427 ModernaTX Baden LR, N Engl J Med, 2020 COVE New Full text Full text ; Full text Full text Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 3 | Healthy adults with no known history of SARS-CoV-2 infection in 99 centers in the US | N=30420 |
Some concerns Details |
|
|
NCT04368728 BioNTech/Fosun Pharma/Pfizer Polack F, N Engl J Med, 2020 Full text Commentary ; Commentary ; Commentary ; Commentary ; Commentary |
RNA based vaccine |
BNT162b2 |
Placebo |
RCTPhase 2/3 | Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA | N=43448 |
Some concerns Details |
|
|
NCT04368728 BioNTech SE, Pfizer Walsh E, N Engl J Med, 2020 New Full text Commentary |
RNA based vaccine |
BNT162b1 10 mcg D1/21 BNT162b1 20 mcg D1/21 BNT162b1 30 mcg D1/21 BNT162b1 100 mcg D1/21 BNT162b2 10 mcg D1/21 BNT162b2 20 mcg D1/21 BNT162b2 30 mcg D1/21 |
BNT162b1 30 mcg D1/21 |
RCTPhase 1 | Healthy SARS-CoV-2 serology/DNA negative adults in four centres in USA | N=195 |
Low Details |
|
The link in the column "Overall risk of bias" provides access to a complete description of the assessment of each risk of bias domain with supports for judgement produced using the Revised Cochrane risk-of-bias tool for randomized trials RoB 2.
The risk of bias by domain as well as overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column "Full description" provides access to the general characteristics of the study.
We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.